诺华去铁药地拉罗司去铁效果如何？

(Deferasirox) is an oral iron chelator produced by Novartis. It was approved by the U.S. Food and Drug Administration (FDA) in November 2005 for the treatment of chronic iron overload caused by blood transfusion in children and adults aged 2 years and older. As of October 31, 2007, there were approximately 36,797 users of deferasirox, of which 31,444 were using post-marketing drugs and 5,353 were using the drug in clinical trials. As the drug has been launched in more than 80 countries and regions, the drug has become more widely used. So, how effective is Novartis’s iron-removing medicine deferasirox?

A multi-center, randomized, open phase III clinical trial in the United States evaluated the safety and tolerability of DFS (deferasirox) and DFO (deferoxamine) by comparing it. At the same time, a biomagnetic susceptibility meter was used to measure changes in liver iron concentration (LIC) before and after administration to quantitatively evaluate the efficacy of DFS. The included subjects were 195 patients with sickle cell anemia, including adults and children, including n=132 in the DFS group and n=63 in the DFO group.

The results showed that the adverse reactions caused by DFS were all mild, including transient nausea, vomiting, diarrhea, abdominal pain, rash, transient non-progressive mild increase in serum creatinine, and reversible liver function abnormalities. Both drugs have been used for more than 1 year, the discontinuation rates are close (DFS 11.4%, DFO 11.1%), and the two drugs have similar effects on reducing dose-dependent LIC. Tests have shown that oral DFS taken once a day is highly tolerable.

Novartis is a pharmaceutical and health company headquartered in Basel, Switzerland. The company was founded in 1996. It was originally formed by the merger of two historic Swiss companies - Ciba-Geigy and Sandoz. After the merger, Novartis has been running smoothly and has become a leading global company. Patients can buy and use the products it produces with confidence.

Recommended hot articles: /newsDetail/92228.html